10 Best Low Priced Biotech Stocks to Buy Now

6. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Stock Price: $3.00

Number of Hedge Fund Holders: 37

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery. Its primary focus is on genetic disease indications and targeted oncology. The company’s Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery.

On May 5, Relay Therapeutics, Inc. (NASDAQ:RLAY) reported its fiscal Q1 2025 results, highlighting significant progress in its clinical programs. It reported a cash runway extended to 2029, with $710 million in cash, cash equivalents, and investments in the quarter. While the company underwent a drop in revenue to $7.7 million, it is focusing on strategic cost reductions, including a reduction in research spending and workforce.

Relay Therapeutics, Inc. (NASDAQ:RLAY) plans to continue executing its clinical programs in the future, with management expressing optimism in its financial strategy to attain its long-term objectives. On May 7, H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) and set a price target of $16.00.